A 2-week Trial Of PF-04991532 In Patients With Type 2 Diabetes
Status:
Completed
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
This will be a 2-week oral dose study of PF 04991532, performed in patients with type 2
diabetes. Safety, pharmacokinetics (how the drug is distributed in the body), and
pharmacodynamics (how the drug works in the body) will be studied. Patients may be asked to
wash off their diabetes medication for 4-6 prior to study drug administration, and they will
remain in the clinical research unit for a total of 20 days for baseline tests, 2 weeks of
dosing, and some follow up tests.